Ketamine for depression: all studies (page 76)

A Comparative Study on the Effectiveness of Electroconvulsive Therapy and Ketamine in Persons Suffering from Treatment-resistant Depressive Disorder

Indian Journal of Psychiatric Nursing July 1, 2024 V. Ramasubramanian, S. Mathumathi, G. Thirumalaisamy et al.

ABSTRACT Depression is a common illness that affects about 3.8% of the population worldwide. Patients with major depression respond to antidepressant treatment, but 10%–20% of them do not improve or show a partial response. It is coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. Treatment-resistant...

DOI: 10.4103/iopn.iopn_93_23 Full text

Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.

Psychopharmacology July 1, 2024 Nathaniel A. Shanok, Sabrina Muzac, Leah Brown et al. 7 citations

Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions;...

DOI: 10.1007/s00213-024-06573-1 Full text Major depressive disorder Mdd Deep tms Brain stimulation +4

Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.

The Australian and New Zealand journal of psychiatry July 1, 2024 Nicollette Lr Thornton, Dean J Wright, Nick Glozier 5 citations

One could argue that we are living through a period of innovation and change in psychiatry unlike that seen before, with repurposed medications emerging as novel treatments. However, despite evidence of enhanced clinical outcomes and potential medium-term savings, delivering these promising interventions is resource-intensive and perceived as difficult in the public sector. Consequently, they...

DOI: 10.1177/00048674241237094 Full text Implementation Public hospital Ketamine therapy Mental health treatment +3

Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Ashok Seshadri, Larry J. Prokop, Balwinder Singh 50 citations

Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...

DOI: 10.1016/j.jad.2024.03.137 Full text Major depressive disorder Clinical trials Dose escalation Intranasal esketamine +5

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Cameron N Calder, Angela T H Kwan, Kayla M Teopiz et al. 31 citations

Ketamine has been established as efficacious in adults living with Treatment-resistant Depression (TRD). Toward providing a quantifiable estimate of the clinical meaningfulness of the therapeutic benefit of ketamine, herein, we conduct a systematic review that aims to report the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH). This systematic review searched Embase,...

DOI: 10.1016/j.jad.2024.04.039 Full text Esketamine Treatment-resistant depression Response Treatment resistant depression +4

Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.

Psychiatry Research July 1, 2024 Ana Paula Anzolin, Daniel Prates Baldez, Bruno Braga Montezano et al. 2 citations

This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial need for rapid-onset treatments in severe depression cases. It introduces an innovative approach to administering an NMDA receptor antagonist, significantly advancing psychopharmacological methods for treating suicidal behaviors as distinct entities,...

DOI: 10.1016/j.psychres.2024.115915 Full text C-ssrs Suicidal ideation Mental health treatment Depression therapy +3

Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.

Biological Psychiatry Global Open Science July 1, 2024 Julia Aepfelbacher, Benjamin Panny, Rebecca B Price 13 citations

Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms of action, it is critical to also consider psychological mechanisms that may contribute to its therapeutic efficacy. The construct of an awe-inducing experience, which is a well-validated psychological phenomenon tied to emotional well-being, had...

DOI: 10.1016/j.bpsgos.2024.100316 Full text Mediation Mediator Psychological Ketamine therapy +4

Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety.

Journal of Psychiatric Research July 1, 2024 Yecun Liu, Jiguo Yang, Yuanxiang Liu 8 citations

Ketamine, electroconvulsive therapy (ECT), and their combination are effective for treating severe depression, but few large-scale studies have compared these. We searched databases for randomized controlled trials (RCTs) using ketamine, ECT, ketamine + ECT, or placebo for severe depression. Standardized measures were efficacy outcomes. Risk of bias was assessed. Stata and ADDIS were used for...

DOI: 10.1016/j.jpsychires.2024.05.022 Full text Ketamine Electroconvulsive therapy Network meta-analysis Severe depression +5

Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.

Psychiatry Research July 1, 2024 Ladan Eshkevari, Michelle Sales, Christina Collins et al. 3 citations

Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD). Recent studies have shown that there are increased levels of pro-inflammatory cytokines in individuals with major depressive disorder (MDD) and those with higher levels of oxidative stress markers have a decreased or null response to conventional antidepressants. Glutathione (GSH) as an...

DOI: 10.1016/j.psychres.2024.115949 Full text Major depressive disorder Neuroplasticity Treatment-resistant depression Glutathione +6

Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A meta-analysis and systematic review of randomized controlled trials.

Asian Journal of Psychiatry July 1, 2024 Muhammad Anas Nayyer, Suchna Meeral Khan, Mohammad Umer et al. 14 citations

Postpartum depression (PPD) is a psychiatric condition affecting women post-childbirth. Medication combined with psychotherapy, is the current protocol for its treatment. A meta-analysis was conducted using RevMan 5.4 to explore the efficacy and safety of peri-partum administration of esketamine for preventing PPD. After searching several databases to retrieve the relevant RCTs, seven were...

DOI: 10.1016/j.ajp.2024.104090 Full text Esketamine Meta-analysis Postnatal depression Postpartum depression +1